Arbutus Biopharma (NASDAQ:ABUS) Cut to Sell at StockNews.com

StockNews.com cut shares of Arbutus Biopharma (NASDAQ:ABUS) from a hold rating to a sell rating in a report released on Thursday.

A number of other equities analysts have also weighed in on ABUS. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research note on Tuesday, January 21st. Chardan Capital reaffirmed a “buy” rating and issued a $5.00 target price (up from $4.50) on shares of Arbutus Biopharma in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $5.50.

Arbutus Biopharma Trading Down 0.6 %

Shares of NASDAQ ABUS opened at $3.30 on Thursday. The firm has a market cap of $625.32 million, a PE ratio of -7.67 and a beta of 1.93. Arbutus Biopharma has a 1-year low of $2.30 and a 1-year high of $4.73. The company has a fifty day moving average price of $3.33 and a 200 day moving average price of $3.62.

Hedge Funds Weigh In On Arbutus Biopharma

A number of large investors have recently modified their holdings of ABUS. Intech Investment Management LLC acquired a new position in shares of Arbutus Biopharma during the 3rd quarter worth about $142,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Arbutus Biopharma by 218.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,212,246 shares of the biopharmaceutical company’s stock worth $4,667,000 after buying an additional 831,663 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Arbutus Biopharma by 453.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,503 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 30,723 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Arbutus Biopharma during the 3rd quarter worth about $754,000. Finally, Rockefeller Capital Management L.P. acquired a new position in shares of Arbutus Biopharma during the 3rd quarter worth about $243,000. 43.79% of the stock is currently owned by institutional investors and hedge funds.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.